1. Home
  2. XIN vs MEIP Comparison

XIN vs MEIP Comparison

Compare XIN & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XIN
  • MEIP
  • Stock Information
  • Founded
  • XIN 1997
  • MEIP 2000
  • Country
  • XIN China
  • MEIP United States
  • Employees
  • XIN N/A
  • MEIP N/A
  • Industry
  • XIN Homebuilding
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • XIN Consumer Discretionary
  • MEIP Health Care
  • Exchange
  • XIN Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • XIN 16.2M
  • MEIP 17.1M
  • IPO Year
  • XIN N/A
  • MEIP 2003
  • Fundamental
  • Price
  • XIN $2.62
  • MEIP $2.15
  • Analyst Decision
  • XIN
  • MEIP Hold
  • Analyst Count
  • XIN 0
  • MEIP 2
  • Target Price
  • XIN N/A
  • MEIP $7.00
  • AVG Volume (30 Days)
  • XIN 11.4K
  • MEIP 8.4K
  • Earning Date
  • XIN 01-01-0001
  • MEIP 05-08-2025
  • Dividend Yield
  • XIN N/A
  • MEIP N/A
  • EPS Growth
  • XIN N/A
  • MEIP N/A
  • EPS
  • XIN N/A
  • MEIP N/A
  • Revenue
  • XIN $667,143,185.00
  • MEIP N/A
  • Revenue This Year
  • XIN N/A
  • MEIP N/A
  • Revenue Next Year
  • XIN N/A
  • MEIP N/A
  • P/E Ratio
  • XIN $0.30
  • MEIP N/A
  • Revenue Growth
  • XIN N/A
  • MEIP 33.76
  • 52 Week Low
  • XIN $2.24
  • MEIP $2.15
  • 52 Week High
  • XIN $7.05
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • XIN 44.57
  • MEIP 27.69
  • Support Level
  • XIN $2.58
  • MEIP $2.28
  • Resistance Level
  • XIN $2.75
  • MEIP $2.35
  • Average True Range (ATR)
  • XIN 0.16
  • MEIP 0.07
  • MACD
  • XIN -0.01
  • MEIP -0.01
  • Stochastic Oscillator
  • XIN 31.58
  • MEIP 0.00

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: